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with Levels of CCR5 Expression and b-Chemokine Production
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Susceptibility of PHA/rIL-2-stimulated PBMC from 14 healthy blood donors for NSI HIV-1 infection was analyzed in relation
to CCR5 expression and b-chemokine production. After 1 week of culture in the presence of rIL-2, but not at the moment of
inoculation, CCR5 surface expression was positively and b-chemokine production was inversely associated with suscepti-
bility to NSI HIV-1 infection. Surprisingly, no association was observed between CCR5 genotype and in vitro NSI HIV-1
susceptibility, which was in agreement with similar levels of CCR5 surface expression and b-chemokine production in
CCR5D32/1 and CCR5 1/1 PBMC after PHA/rIL-2 stimulation. In contrast to what was observed in vitro, CCR5 genotype
did associate with CCR5 surface expression levels in vivo in resting as well as in activated CD41 T cell populations that were
identified by the expression of CD45RO, CD27, HLA-DR, and CD69. The association between CCR5 expression and
susceptibility to infection by NSI HIV-1 observed in vitro might offer an explanation for the in vivo observed protective effect
of CCR5 polymorphisms that influence CCR5 expression on disease progression. © 2000 Academic Press
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1INTRODUCTION
Non-syncytium-inducing (NSI) variants of HIV-1 use
the b-chemokine receptor CCR5 as a cofactor for entry of
arget cells (Deng et al., 1996; Dragic et al., 1996; Alkhatib
t al., 1996; Choe et al., 1996; De Roda Husman et al.,
999b; Zhang, L., et al., 1998; Zhang, Y.-J., et al., 1998;
jo¨rndal et al., 1997). The relevance of this receptor in
IV-1 infection and AIDS pathogenesis has become
lear by virtue of genetic polymorphisms influencing its
xpression levels. In the human Caucasian population
he most prevalent polymorphism in the coding region of
CR5 is a 32-bp deletion (CCR5D32). Individuals ho-
ozygous for CCR5D32 (CCR5 D32/D32), who conse-
uently lack CCR5 cell surface expression (Wu et al.,
997; Liu et al., 1996), are protected from HIV-1 infection
Liu et al., 1996; Huang et al., 1996; Samson et al., 1996;
Dean et al., 1996; Michael et al., 1997; Zimmerman et al.,
997). However, the existence of HIV-1-infected CCR5
32/D32 individuals showed that this protection is not
bsolute (Balotta et al., 1997; Theodorou et al., 1997;
’Brien et al., 1997; Biti et al., 1997), which might be
xplained by transmission of viruses that use CXCR4 as
coreceptor (Michael et al., 1998). CCR5D32 heterozy-
ous individuals (CCR5 D32/1) were shown not to be
1 Current address: Department of Cellular Biochemistry, The Nether-
ands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The
etherlands.
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237rotected from infection, but CCR5D32 heterozygosity
as been associated with a mean elongated AIDS-free
urvival period compared to individuals with the wild-
ype CCR5 genotype (CCR5 1/1) (Dean et al., 1996; De
oda Husman et al., 1997; Huang et al., 1996; Meyer et
l., 1997; Eugen-Olsen et al., 1997; Michael et al., 1997;
immerman et al., 1997). More recently, also other poly-
orphisms in the coding region (Quillent et al., 1998) and
he promoter region (McDermott et al., 1998; Martin et al.,
998; Mummidi et al., 1998) of CCR5 have been shown to
e associated with disease progression. In line with the
n vivo observations, PBMC from CCR5 D32/1 individu-
als were shown to be less susceptible to NSI HIV-1 in
vitro (Paxton et al., 1998; Wu et al., 1997; Blaak et al., 1998;
im et al., 1998) and in vivo in PBL-SCID mice (Picchio et
al., 1997) compared to PBMC from CCR5 1/1 individu-
als. The on average lower proportion of CCR5-express-
ing CD41 T cells and lower CCR5 surface expression
levels on PBMC (Wu et al., 1997; De Roda Husman et al.,
1999a) may result in slower spread of the virus and
hence explain reduced NSI HIV-1 susceptibility of PBMC
and slower disease progression in CCR5 D32/1 individ-
uals.
An additional factor influencing HIV-1 replication is the
presence of the natural ligands of CCR5. These ligands,
RANTES, MIP-1a, and MIP-1b, were shown to inhibit NSI
replication in vitro (Paxton et al., 1996; Deng et al., 1996;
ragic et al., 1996; Alkhatib et al., 1996; Cocchi et al.,
995; Margolis et al., 1998; Kinter et al., 1996) and high
1ndogenous production by PBMC and/or CD4 T lym-
hocytes was associated with protection from HIV-1 in-
0042-6822/00 $35.00
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238 BLAAK ET AL.fection in vivo (Paxton et al., 1998; Furci et al., 1997;
agury et al., 1998) and HIV-1 disease progression (Saha
t al., 1998). The inhibitory effect of b-chemokines is
proposed to act through blocking of the coreceptor as
well as through down-regulation of CCR5 on the cell
surface (Alkhatib et al., 1997). The relevance of b-che-
mokine production in HIV-1 disease progression was
recently supported by the identification of a polymor-
phism in the RANTES promoter that associates with
reduced RANTES secretion and concomitantly with re-
duced CD41 T cell decline (Liu et al., 1999).
We analyzed here CCR5 expression levels and b-che-
mokine production of PBMC and CD8-depleted PBMC
after in vitro stimulation with phytohemagglutinin (PHA)
and rIL-2. In parallel, the susceptibility for a panel of
primary NSI variants was determined and the relation
with CCR5 and b-chemokine levels was studied.
RESULTS
usceptibility of total PBMC and CD8-depleted PBMC
Three-day PHA-stimulated PBMC and CD82PBMC de-
rived from 14 healthy donors were inoculated with a
panel of seven primary NSI variants and further cultured
in the presence of rIL-2. The donors were selected based
on their CCR5 genotype: 7 had the CCR5 D32/1 and 7
the CCR5 1 genotype. After 14 days of culture the TCID50
was determined for each virus/donor combination. Since
cells from each donor were inoculated with the same
stock of each virus, the differences in the virus titers are
a reflection of differences in NSI HIV-1 susceptibility of
2
FIG. 1. Susceptibility total PBMC and CD82 PBMC for NSI HIV-1. The
of culture. For each donor, 7 CCR5 1/1 and 7 CCR5 D32/1 individuals
( ) are depicted. Bars represent the standard error of the mean. Di
ndicated by *P , 0.05 and ** 0.05 , P , 0.06.the cells. Paired analysis of PBMC and CD8 PBMC
showed that the susceptibility was similar in 11/14 cases(Fig. 1). For 1 donor the susceptibility of PBMC was
higher than that of CD82 PBMC (donor 1, average 50%
issue culture infections dose (TCID50) 10
4.60 vs 104.22,
respectively, P 5 0.028, paired t test). For 2 donors the
inverse was observed, with reduced susceptible PBMC
compared to CD82 PBMC (donor 7, average TCID50 10
4.05
vs 104.30, respectively, P 5 0.058; donor 10, average
CID50 10
3.40 vs 104.25, respectively, P 5 0.002). Although
interindividual differences in susceptibility were ob-
served, these differences were not related to differences
in CCR5 genotype (Fig. 1).
Correlates of NSI HIV-1 susceptibility
For the PBMC of each donor the average TCID50 of
even NSI variants was used as a measure for NSI HIV-1
usceptibility. In order to classify the relative NSI HIV-1
usceptibility of the PBMC from each of the 14 donors,
he median of the 14 average TCID50 values was deter-
mined (104.15). PBMC with an average TCID50 below that
f the group median were defined as having relatively
ow NSI HIV-1 susceptibility, PBMC with an average
CID50 above that of the group median were defined as
having relatively high NSI HIV-1 susceptibility (Table 1).
Thus 7 donors with less and 7 donors with more sus-
ceptible PBMC could be identified (group average TCID50
103.59 and 104.50, respectively). For these two groups of
donors CCR5 expression prior to stimulation (t 5 23)
and CCR5 expression and b-chemokine production after
days of PHA stimulation (i.e., just prior to inoculation,
5 0) were compared. In parallel cultures that were
ock infected, the CCR5 expression and b-chemokine
of seven NSI viruses was determined by p24 production after 14 days
verage 10log TCID50 on parallel cultured PBMC (h) and CD8
2 PBMC
s were analyzed with the paired t test and statistical significance isTCID50
, the aproduction after further propagation in the presence of
rIL-2 (t 5 6) were analyzed.
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239IN VITRO SUSCEPTIBILITY TO NSI HIV-1 INFECTIONThe percentage of CCR51 cells and the MFICCR5 in the
D41 cell population prior to stimulation and at the
moment of inoculation did not differ between donors with
relatively low and donors with relatively high in vitro NSI
HIV-1 susceptibility (Fig. 2). However, in vitro susceptibil-
ity of PBMC was highly associated with the levels of
CCR5 expression observed after 6 days of mock infec-
tion (42 and 20% CCR51 CD41 T cells in PBMC with high
nd low susceptibility, respectively, P 5 0.002; MFICCR5 of
25 and 14 in PBMC with high and low susceptibility,
respectively, P 5 0.013; Student’s t test; Fig. 2).
Similarly, at the end of 3-day PHA stimulation no dif-
ference was observed in the mean production of MIP-1a,
IP-1b, and RANTES between PBMC with relatively high
nd relatively low NSI HIV-1 susceptibility (Fig. 3a). After
days of mock infection, the mean level of each b-che-
mokine was higher in the cell cultures with the lowest
T
Classification of 14 Blood Donors According to
PBMC with relatively low in vitro NSI HIV-1 susceptibility
Donor Average log TCID50
a CCR5 genotypeb
14 2.39 1/1
10 3.40 1/1
5 3.57 D32/1
11 3.72 1/1
2 3.87 D32/1
7 4.05 D32/1
4 4.12 D32/1
a Calculated average 10log TCID50 values of seven NSI variants.
b 1/1, CCR5 wild-type individuals; D32/1, individuals heterozygous
FIG. 2. CCR5 expression on cells with high and low susceptibility for
the mean fluorescence intensity of the CD41 T cell population (b) was co
CCR5 expression was analyzed prior to stimulation (t 5 23), after 3 d
of mock infection in the presence of rIL-2 (t 5 6). Error bars represent the sta
test; statistical significance is indicated by *P , 0.05.susceptibility (mean values: MIP-1a, 10.6 vs 2.7 ng/ml,
P 5 0.025; MIP-1b, 5.5 vs 2.3 ng/ml, P 5 0.042; RANTES,
.4 vs 0.6 ng/ml, P 5 0.010, Student’s t test; Fig. 3b). Note
hat the approximately 4-fold lower level of chemokine
roduction observed at t 5 6 compared to t 5 0 (Fig. 3)
is likely explained by a 10-fold lower cell concentration
(0.5 3 106 vs 5 3 106 cells/ml) in combination with a
-fold longer cultivation period (6 vs 3 days).
Similar to what we observed for PBMC, the NSI HIV-1
usceptibility of CD82PBMC was associated with the
levels of CCR5 surface expression and b-chemokine
roduction at t 5 6 (data not shown).
Association between CCR5 surface expression and
b-chemokine production
Both high CCR5 surface expression and low b-chemo-
kine production after PHA/rIL-2 stimulation (i.e., at t 5 6)
Vitro NSI HIV-1 Susceptibilities of Their PBMC
PBMC with relatively high in vitro NSI HIV-1 susceptibility
Donor Average log TCID50
a CCR5 genotypeb
12 4.17 1/1
13 4.20 D32/1
8 4.42 1/1
9 4.55 D32/1
1 4.6 1/1
3 4.72 1/1
6 4.82 D32/1
32-bp deletion in CCR5.
-1 infection. The percentage of CCR5-expressing CD41 T cells (a) and
d for PBMC with relative high (h) and relative low ( ) susceptibility.
HA stimulation, just prior to virus inoculation (t 5 0) and after 6 daysABLE 1
the inNSI HIV
mpare
ays of P
ndard error of the mean. Differences were analyzed with the Student
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240 BLAAK ET AL.were associated with high in vitro NSI HIV-1 susceptibil-
ity. Since it was shown previously that low CCR5 cell
surface expression is associated with high b-chemokine
evels (Paxton et al., 1998), likely due to internalization of
he receptor after chemokine binding (Alkhatib et al.,
997), we analyzed the correlation between b-chemokine
production and CCR5 expression, in relation to suscep-
tibility. No (or a weak) correlation was observed between
the percentage of CCR51CD41 T cells and the log-trans-
ormed values of levels MIP-1a and MIP-1b after PHA/
IL-2 stimulation (Rp 5 20,455, P 5 0.10; and Rp 5
20.301, P 5 0.30, respectively; not shown). A strong
inverse correlation was observed, however, for the per-
centage of CCR5-expressing CD41 T cells and the level
f RANTES production (Rp 5 20.630, P 5 0.016; Fig. 4).
t is clear from Fig. 4 that the PBMC with low suscepti-
ility have both a relatively low proportion of CCR5-
xpressing CD41 T cells and a relatively high level of
ANTES production.
CR5 genotype and in vitro NSI HIV-1 susceptibility
In contrast to what was found previously by some
(Paxton et al., 1998; Blaak et al., 1998; Wu et al., 1997; Kim
et al., 1998), but in agreement with others (Picchio et al.,
1997), we did not observe that susceptibility to NSI HIV-1
infection in vitro was associated with the CCR5 genotype
(Table 1). In order to understand the basis of this disso-
ciation, we analyzed the association of CCR5 genotype
with in vitro induced CCR5 surface expression and
b-chemokine production after PHA/rIL-2 stimulation. As
was shown previously (Wu et al., 1997; De Roda Husman
et al., 1999a), the percentage of CCR5-expressing
1
FIG. 3. Chemokine production of cells with high and low susceptibili
supernatant was compared for PBMC with relative high (h) and rela
arvested after 3 days of stimulation with PHA (t 5 0; a) and again after
he standard error of the mean. Differences were analyzed with the Stud
y *P , 0.05.CD4 T cells was associated with the CCR5 genotype
prior to stimulation (24% in CCR5 1/1 and 14% in CCR5D32/1, P 5 0.006, Students t test; Fig. 5a, left). However,
after PHA/rIL-2 stimulation this association was lost (31%
CCR5-expressing CD41 T cells both in CCR5 1/1 and in
CCR5 D32/1 PBMC, P 5 0.96, Student’s t test; Fig. 5a,
ight). The similar CCR5 expression levels in CCR5 1/1
nd CCR5 D32/1 cells after stimulation could be ex-
SI HIV-1 infection. MIP-1a, MIP-1b, and RANTES production in culture
w ( ) susceptibility. Analysis was performed on culture supernatant
of mock infection in the presence of rIL-2 (t 5 6; b). Error bars represent
st on the log-transformed values and statistical difference is indicated
FIG. 4. Correlation between RANTES production, percentage of
CCR5-expressing CD41 T cells, and susceptibility. The level of RANTES
in culture supernatants and the percentages of CCR5-expressing cells
in the CD41 T cell populations measured 6 days after mock infection
are depicted for the PBMC of each donor. Correlation analysis was
performed with the Pearson correlation coefficient after log transfor-
mation of the levels of RANTES. The susceptibility of the cells of eachty for N
tively lo
6 daysdonor is depicted by the color of the symbol (E, low; F, high) and the
numbers next to the symbol, representing the average 10log TCID50.
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241IN VITRO SUSCEPTIBILITY TO NSI HIV-1 INFECTIONplained by an on average higher up-regulation in CCR5
D32/1 (on average, 117%; range, 12 to 140%) com-
ared to CCR5 1/1 (on average, 17%; range, 216 to
31%) cells. Similar observations were made for CCR5
xpression as measured by the MFI (not shown).
In addition, no CCR5 genotype-related differences in
b-chemokine production were observed after PHA/rIL-2
stimulation (mean values of 22.1 and 6.0 ng/ml for CCR5
1/1 and CCR5 D32/1 PBMC, respectively; P 5 0.13; Fig.
5b). Of interest, the three CCR5 1/1 PBMC with the
highest b-chemokine production levels were the three
CR5 1/1 PBMC with reduced HIV-1 susceptibility (Ta-
le 1). From the inverse relation between b-chemokine
production and CCR5 expression (Fig. 4) it follows that
the relatively high b-chemokine production by some of
he CCR5 1/1 PBMC coincides with low CCR5 expres-
ion levels, which might account for the on average
qual CCR5 expression levels, which might account for
he on average equal CCR5 expression levels between
CR5 1/1 and CCR5 D32/1 PBMC. Indeed, stratifica-
ion of the PBMC according to genotype suggests that
he percentage of CCR5-expressing cells may largely be
etermined by the combination of the genotype and the
evel of b-chemokine production (Fig. 6).
CR5 genotype and CCR5 surface expression
n in vivo activated cells
The absence of an association between CCR5 geno-
ype and CCR5 expression after in vitro stimulation
prompted us to study the association between CCR5
FIG. 5. CCR5 expression and b-chemokine production in vitro stimula
D41 T cells prior to stimulation (t 5 23: a, left) and in 6-day mock-inf
CCR5 1/1 individuals. The total level of b-chemokines in the culture su
CR5 1/1 PBMC (b). Horizontal bars indicate average value of the per
standard deviation. Differences were analyzed with the Student t test.genotype and CCR5 surface expression on in vivo acti-
vated cells. To this purpose CCR5 expression was ana-lyzed on resting and activated CD41 T cells in unstimu-
lated PBMC from the 14 healthy blood donors. In vivo
activation was identified by cellular expression of
CD45RO in the absence of CD27 expression (Hamann et
al., 1997; Baars et al., 1995) or in combination with either
LA-DR or CD69 expression. The proportion of CCR5-
xpressing cells was very low within the naı¨ve CD41 T
ell population (average values: CD45RO2/HLA-DR2, 7%;
D45RO2/CD692, 3%; CD45RO2CD271, 0.7%; Fig. 7a)
nd not statistically different between CCR5 1/1 and
CR5 D32/1 PBMC (not shown). The proportion of
CCR5-expressing cells was highest in the activated
memory CD41 T cells (average values: CD45RO1/HLA-
DR1, 50%; CD45RO1/CD691, 62%; CD45RO1CD272, 60%;
Fig. 7a) and intermediate in the resting memory CD41 T
ells (average values: CD45RO1/HLA-DR2, 29%;
D45RO1/CD692, 25%; CD45RO1CD271, 22%; Fig. 7a).
The association between the level of CCR5 expression
and activation status of the cells is in agreement with
previous observations (Bleul et al., 1997; Ostrowski et al.,
1998; De Roda Husman et al., 1999a). Both in the resting
nd in the activated memory CD41 T cell populations the
proportion of CCR5 surface-expressing cells (Fig. 7bc)
and CCR5 expression as measured by MFI (not shown)
were on average lower in CCR5 D32/1 compared to
CCR5 1/1 PBMC.
DISCUSSION
Susceptibility of PBMC and CD8-depleted PBMC for in
vitro NSI HIV-1 infection was associated with the expres-
R5 1/1 and CCR5 D32/1 PBMC. The percentage of CCR5-expressing
BMC (t 5 6: a, right) was compared for PBMC from CCR5 D32/1 and
ant of 6-day mock-infected PBMC was compared for CCR5 D32/1 and
e of CCR51 CD41 cells (a) or total b-chemokine production (b) and theted CC
ected P
pernatsion of the coreceptor for NSI variants, CCR5, and the
levels of its natural ligands, the b-chemokines, produced
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242 BLAAK ET AL.during culture. This association was only observed for
3-day PHA-stimulated PBMC that had subsequently
been cultured for 6 days in the presence of rIL-2, paral-
leling 6 days of infection. The absence of an association
of HIV-1 susceptibility with CCR5 surface expression and
b-chemokine levels immediately after 3-day PHA stimu-
lation, so at the moment of inoculation, suggests that
under the presently used conditions virus production is
determined by the capacity of the virus to spread through
culture, rather than by the efficiency of the initial inocu-
lation.
In the present study we confirmed the existence of an
association between ex vivo CCR5 expression levels and
CCR5 genotype (Wu et al., 1997; De Roda Husman et al.,
1999a) and extended these observations by showing
that this association exists for both resting and in vivo
activated CD41 T cells. However, after in vitro PHA and
IL-2 stimulation this association was lost, apparently
ue to a relatively higher up-regulation of CCR5 in the
CR5D32 heterozygous PBMC. CCR5 can be down-reg-
lated upon binding of its natural ligands (Alkhatib et al.,
997) and high b-chemokine levels may consequently
esult in reduced CCR5 expression. In agreement with
his is the inverse correlation we here observed between
ANTES production and CCR5 surface expression. In
his view, the dissociation between CCR5 genotype and
CR5 expression in vitro might be due to levels of b-che-
mokines and CCR5 genotype together determining the
ultimate levels of CCR5 cell surface expression. In vivo,
however, the CCR5 genotype may be decisive and a role
for down-modulation by chemokines limited to inflamma-
tory sites. Down-modulation of CCR5 by RANTES (and to
a lesser extent by MIP-1a and MIP-b) may explain the
FIG. 6. Correlation between the percentages of CCR5-expressing
epicted are the percentages of CCR5-expressing cells in the CD41 T c
of RANTES (b) in culture supernatants, all measured 6 days after moc
colors indicate the different CCR5 genotypes: E, CCR5D32/1 PBMC;ssociation between b-chemokine production and re-
uced in vitro susceptibility for NSI HIV-1. In addition the
i
eb-chemokines may directly interfere with HIV-1 entry
(Alkhatib et al., 1997).
The absent correlation between CCR5 genotype and
CCR5 expression levels under the currently used exper-
imental conditions likely translates into the lack of an
association between CCR5 genotype and NSI HIV-1 sus-
ceptibility. This observation contrasts with previous stud-
ies (Paxton et al., 1998; Wu et al., 1997; Blaak et al., 1998;
Kim et al., 1998), which might reflect different cultivation
conditions that differentially influence b-chemokine ex-
ression and hence CCR5 expression levels. While the
resent data indicate that the CCR5 expression level,
nd not CCR5 genotype per se, is an important determi-
ant for NSI HIV-1 susceptibility in vitro, they do not
xclude the possibility that CCR5 genotype, by determin-
ng in vivo CCR5 expression, influences HIV-1 replication
n vivo. Indeed, in the PBL-SCID mouse model, replica-
ion of NSI HIV-1 was significantly lower in mice repop-
lated with PBMC from a CCR5D32 heterozygous donor
ompared to mice repopulated with CCR5 1/1 PBMC
Picchio et al., 1997). In analogy, reduced percentages of
CR5-expressing CD41 T cells and reduced CCR5 den-
ity at the cell surface may interfere with the efficiency of
n vivo HIV-1 infection and viral spread through the hu-
an body. In agreement, we previously demonstrated
hat among individuals with a CCR5 1/1 genotype, a
reduced CCR5 surface expression correlated with a bet-
ter prognosis of HIV-1 infection (De Roda Husman et al.,
1999a). The in vivo association between CCR5 genotype
and expression levels (this study; Wu et al., 1997; De
Roda Husman et al., 1999a) might offer an explanation
or the observed protective effect of the CCR5D32 het-
rozygous genotype on disease progression of HIV-1-
nd b-chemokine production stratified according to CCR5 genotype.
ulations in relation to the total levels of b-chemokines (a) and the levels
tion. Each symbol represents the PBMC from one donor; the different
5 1/1 PBMC.cells a
ell popnfected individuals (Dean et al., 1996; De Roda Husman
t al., 1997; Huang et al., 1996; Meyer et al., 1997; Eugen-
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243IN VITRO SUSCEPTIBILITY TO NSI HIV-1 INFECTIONOlsen et al., 1997; Michael et al., 1997; Zimmerman et al.,
997; Morawetz et al., 1997). Indeed, the observed lower
ean viral load early in infection in CCR5D32 heterozy-
ous compared to CCR5 1/1 individuals may be a
eflection of impaired virus replication (De Roda Husman
t al., 1997; Huang et al., 1996; Meyer et al., 1997).
MATERIALS AND METHODS
Cells and viruses
PBMC were isolated from buffy coats from 14 healthy
plasmaferesis donors by Ficoll–Paque isolation. PBMC
FIG. 7. Ex vivo CCR5 expression in resting and activated CD41 T ce
ells (d) and in naı¨ve (h), resting memory ( ), and activated m
(b) and the activated CD41 memory T cells (c) the expression for CCR
defined as indicated in the figures. Vertical bars (a) represent standard
percentage of CCR51CD41 T cells within each CD41 T cell subset anwere stored in liquid nitrogen until usage. Three days
prior to infection (t 5 23) thawed PBMC (5 3 106/ml)were stimulated with PHA (1 mg/ml). At the day of infec-
tion (t 5 0), PHA-supplemented medium was removed
and from part of the PHA-stimulated PBL (PHA-PBL),
CD81 T cells were depleted by the use of CD8-coated
immunomagnetic beads (miniMACS, CLB, Amsterdam,
The Netherlands). Both total PHA-PBL and CD82 PHA-
PBL were suspended in rIL-2 (Proleukin, Chiron Benelux
BV, Amsterdam, The Netherlands; 20 U/ml) supple-
mented medium (0.5 3 106 cells/ml). Cells used in the
usceptibility assay were plated in 96-well plates (50,000
ells per well) and cultured for 14 days. Parallel (mock-
nfected) cultures for FACS analysis and determination of
ts. The average percentage of CCR5-expressing cells in total CD41 T
( ) CD41 T cells was determined (a). For the resting CD41 memory
1 and CCR5 1/1 PBMC was analyzed separately. The subsets were
f the mean, and horizontal bars (b,c) indicate the average values of the
tandard deviation. Differences were analyzed with the Student t test.ll subse
emory
5 D32/b-chemokine production in supernatant were grown in
6-well plates, at the same cell concentration.
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244 BLAAK ET AL.Viruses were seven biological HIV-1 clones obtained
during the early, asymptomatic stage of infection from
three participants [ACH15 (n 5 4), ACH372 (n 5 2), and
ACH456 (n 5 1)] of the Amsterdam Cohort Studies on
HIV-1 infection and AIDS. Participants and the moment of
virus isolation were described in more detail elsewhere
(nontransmitters from couples D4, D8, and D7, respec-
tively (Blaak et al., 1998). All HIV-1 clones had the NSI
phenotype as determined on the MT2 cell line (Koot et
al., 1992).
Susceptibility assay
The seven NSI HIV-1 clones were titrated on PHA-PBL
(on average 67% of CD31 T cells were CD41 and 25%
were CD81) and CD82 PHA-PBL (on average 93% of
D31 T cells were CD41 and 0.2% were CD81) from each
of the 14 blood donors. Briefly, the cells were inoculated
with serial fivefold dilutions of each virus stock and
cultures were maintained for 14 days. At day 7, one-third
of the medium was removed and replaced by fresh
rIL-2-supplemented medium. At day 14 virus production
was determined in an in-house p24 ELISA (Tersmette et
al., 1989) and the TCID50 per milliliter of virus stock was
etermined. For each donor the average TCID50 of seven
NSI viruses was used as a measure of NSI HIV-1 sus-
ceptibility of their PBMC and CD82PBMC.
CR5 genotyping
Genomic DNA was isolated from fresh PBMC (Qiagen,
estburg, Hilden, Germany). CCR5 genotyping was per-
ormed by PCR analysis using primers flanking the 32-bp
eletion in CCR5 (De Roda Husman et al., 1997).
ACS analysis
Prior to stimulation (t 5 3), after PHA stimulation (i.e.,
ust before inoculation, t 5 0), and after 6 days of mock
nfection in the presence of rIL-2 (t 5 6), cells were
tained with a combination of monoclonal antibodies
mAbs) directed against CD4 (–TC, Caltag, Burlingame,
A) and CCR5 (5G7–FITC, PharMingen, San Diego, CA).
ince after 1 week of culture the proportion of viable
D41 T cells decreases rapidly (unpublished observa-
tion), and hence most of the viral spread through the
culture will occur during the first week, no analysis was
performed on cells during the second week of the culture
period. To monitor the efficiency of CD8 depletion, cells
were stained with a combination of mAbs directed
against CD3 (–PE) CD8 (–FITC), and CD4 (–TC) (all mAbs
from Caltag).
In order to determine CCR5 expression levels on in
vivo activated CD41 T cells, cryopreserved, unstimulated
PBMC were stained with a combination of (1) CD4
(–PERCP, Becton Dickinson, San Jose, CA), CD45RO
(–APC, Becton Dickinson), HLA-DR (–PE, Caltag), and
CCR5 (5G7–FITC, PharMingen); (2) CD4 (–PERCP, BectonDickinson), CD45RO (–PE, Dako, Glostrup, Denmark),
CD69 (–APC, Becton Dickinson), CCR5 (5G7–FITC,
PharMingen); (3) CD4 (–PERCP, Becton Dickinson),
CD45RO (–APC, Becton Dickinson), CD27 (–FITC, CLB,
Amsterdam, The Netherlands), CCR5 (5G7–PE, PharMin-
gen). All incubation steps were performed for 20 min at
4°C. Expression of the markers was analyzed with a
FACScan or a FACScaliber (both from Becton Dickinson).
b-Chemokine production
At t 5 0 and t 5 6, 200 ml of cell-free culture super-
natant was sampled and stored at 220°C until analysis.
The presence of MIP-1a, MIP-1b, and RANTES in the
upernatant was determined by ELISA (R&D Systems,
inneapolis, MN).
tatistical analyses
Comparisons between cells with the CCR5 1/1 and
CCR5 D32/1 genotype, between cells with high and low
susceptibility, and between total PBMC and CD82 PBMC
ere made with the Student’s t test. In the cases of
omparisons of b-chemokine levels, statistics were per-
formed on the log-transformed values. The correlation
between CCR5 expression and the log-transformed val-
ues of RANTES was determined with the Pearson corre-
lation coefficient. Normality of the samples was deter-
mined by the Shapiro–Wilks test for normality. All statis-
tical analyses were performed by the use of SPSS 7.5 for
windows.
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